| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.30(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
24,200 |
99,487 |
198,726 |
249,694 |
| Total Sell Value |
$1,216,805 |
$4,824,734 |
$8,206,765 |
$10,494,293 |
| Total People Sold |
3 |
8 |
9 |
12 |
| Total Sell Transactions |
4 |
12 |
20 |
35 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kakkis Emil D |
President & CEO |
• • – |
2019-03-01 |
4 |
D |
$67.55 |
$189,275 |
D/D |
(2,802) |
467,670 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
470,472 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2019-03-01 |
4 |
D |
$67.55 |
$66,267 |
D/D |
(981) |
69,156 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
70,137 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2019-03-01 |
4 |
D |
$67.55 |
$41,003 |
D/D |
(607) |
21,711 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
22,318 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-03-01 |
4 |
D |
$67.55 |
$58,093 |
D/D |
(860) |
20,321 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
21,181 |
|
- |
|
| Huizenga Theodore Alan |
VP, Controller and PAO |
• – – |
2019-03-01 |
4 |
D |
$67.55 |
$16,617 |
D/D |
(246) |
15,649 |
|
- |
|
| Huizenga Theodore Alan |
VP, Controller and PAO |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,390 |
15,895 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2019-01-30 |
4 |
D |
$48.85 |
$79,919 |
D/D |
(1,636) |
16,364 |
|
- |
|
| Huizenga Theodore Alan |
VP, Controller and PAO |
• – – |
2019-01-02 |
4 |
OE |
$21.00 |
$51,408 |
D/D |
2,448 |
14,505 |
|
- |
|
| Aliski William |
Director |
– • – |
2018-12-07 |
4 |
AS |
$49.69 |
$298,140 |
I/I |
(6,000) |
90,350 |
|
- |
|
| Aliski William |
Director |
– • – |
2018-11-08 |
4 |
AS |
$55.67 |
$334,020 |
I/I |
(6,000) |
96,350 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2018-10-31 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
62,128 |
|
- |
|
| Aliski William |
Director |
– • – |
2018-10-08 |
4 |
AS |
$73.38 |
$440,280 |
I/I |
(6,000) |
102,350 |
|
- |
|
| Hogenhuis Wladimir |
Chief Operating Officer |
• – – |
2018-10-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2018-09-25 |
4 |
AS |
$90.07 |
$603,469 |
D/D |
(6,700) |
50,128 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2018-09-25 |
4 |
OE |
$0.82 |
$2,730 |
D/D |
3,350 |
56,828 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2018-08-21 |
4/A |
S |
$78.53 |
$392,650 |
D/D |
(5,000) |
14,181 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2018-08-21 |
4/A |
OE |
$54.50 |
$272,500 |
D/D |
5,000 |
19,181 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2018-08-21 |
4 |
S |
$78.53 |
$392,650 |
D/D |
(5,000) |
9,181 |
|
- |
|
| Aliski William |
Director |
– • – |
2018-08-08 |
4 |
S |
$76.66 |
$287,475 |
D/D |
(3,750) |
72,610 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2018-07-16 |
4 |
D |
$84.35 |
$54,743 |
D/D |
(649) |
17,681 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2018-06-21 |
4 |
AS |
$82.77 |
$101,476 |
D/D |
(1,226) |
14,181 |
|
- |
|
628 Records found
|
|
Page 16 of 26 |
|
|
1.49 (3.86%) 
